EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical Value of Tocilizumab in Reducing Mortality in Refractory Septic Shock in Children with Hematologic and Non-Hematologic Diseases

En-Pei Lee, Jainn-Jim Lin iD, Shih-Hsiang Chen iD, Oi-Wa Chan, Ya-Ting Su, Man-Ru Hsiao, Shao-Hsuan Hsia, Han-Ping Wu iD

Cells · 2025

DOI: 10.3390/cells14060441 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, 2025. Verfasst von En-Pei Lee und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Critical Care Medicine, Department of Pediatrics, Chang Gung Memorial Hospital at Linko, Kweishan, Taoyuan 33305, Taiwan. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Shock, Septic, Hematologic Diseases. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chang Gung Memorial Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pediatric sepsis remains the main cause of morbidity and mortality among children. Interleukin (IL)-6 is usually produced after infection, and elevated IL-6 levels may cause multisystemic damage. This study aimed to evaluate the effect of tocilizumab, an IL-6 receptor antibody, on children with septic shock.

Methods

We conducted a retrospective cohort study of children diagnosed with septic shock and admitted to the pediatric intensive care unit (PICU) between 2018 and 2024. Tocilizumab was administered within 24 h to patients with high IL-6 levels who developed refractory septic shock. Outcomes, including 28-day mortality, morbidity, length of PICU stay, and shock duration, were analyzed between septic children with different etiologies and differed treatments.

Results

Fifty-four children with refractory septic shock were included. Patients treated with tocilizumab (n = 21) showed improved outcomes compared to those without tocilizumab (n = 33), including shorter PICU stays and lower mortality rates (14.2% vs. 54.5%, p = 0.03). Subgroup analysis revealed that in the non-hematologic group, tocilizumab-treated patients had a 0% mortality rate compared to 50% in untreated patients (p = 0.006). In the hematologic group, tocilizumab-treated patients exhibited a 27.2% mortality rate compared to 61.5% in untreated patients (p = 0.09). Trends in IL-6 levels (D1 to D7) were significantly higher in non-survivors compared to survivors and in patients with hematological malignancies compared to those without. No adverse events, including secondary infections or long-term liver impairment, were observed.

Conclusions

Tocilizumab appears to mitigate systemic inflammation and improve outcomes in children with refractory septic shock and elevated IL-6 levels. Further prospective studies are warranted to confirm these findings and establish treatment guidelines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedShock, SepticHematologic DiseasesHumansMaleFemaleChildChild, PreschoolRetrospective StudiesInfantInterleukin-6Intensive Care Units, PediatricTreatment OutcomeAdolescent

Stichwörter der Autor:innen

biomarkerschildrencytokine storminterleukin-6septic shock

Substanzen

Antibodies, Monoclonal, HumanizedtocilizumabInterleukin-6

Autor:innen und Institutionen

  • Division of Pediatric Critical Care Medicine, Department of Pediatrics, Chang Gung Memorial Hospital at Linko, Kweishan, Taoyuan 33305, Taiwan.
  • College of Medicine, Chang Gung University, Taoyuan 33305, Taiwan.
  • Divisions of Hematology and Oncology, Department of Pediatrics, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan 33315, Taiwan.
  • Division of Pediatric Endocrinology and Genetics, Department of Pediatrics, Chang Gung Memorial Hospital, Taipei 10507, Taiwan.
  • Department of Pharmacy, Chang Gung Memorial Hospital, Taoyuan 33315, Taiwan.
  • Physician Assistant Department, University of Maryland Eastern Shore, Princess Anne, MD 21853, USA.

ORCID-Profile: Jainn-Jim Lin, Shih-Hsiang Chen, Han-Ping Wu

Förderung

  • Chang Gung Memorial Hospital

Zitieren

APA

Lee, E. P., Lin, J. J., Chen, S. H., Chan, O. W., Su, Y. T., Hsiao, M. R., Hsia, S. H., & Wu, H. P. (2025). Clinical Value of Tocilizumab in Reducing Mortality in Refractory Septic Shock in Children with Hematologic and Non-Hematologic Diseases. Cells. https://doi.org/10.3390/cells14060441

Vancouver

Lee EP, Lin JJ, Chen SH, Chan OW, Su YT, Hsiao MR, et al. Clinical Value of Tocilizumab in Reducing Mortality in Refractory Septic Shock in Children with Hematologic and Non-Hematologic Diseases. Cells. 2025. doi:10.3390/cells14060441

BibTeX
@article{Lee2025,
  author = {Lee, En-Pei and Lin, Jainn-Jim and Chen, Shih-Hsiang and Chan, Oi-Wa and Su, Ya-Ting and Hsiao, Man-Ru and Hsia, Shao-Hsuan and Wu, Han-Ping},
  title = {Clinical Value of Tocilizumab in Reducing Mortality in Refractory Septic Shock in Children with Hematologic and Non-Hematologic Diseases},
  journal = {Cells},
  year = {2025},
  doi = {10.3390/cells14060441}
}
Kostenlos starten →